Waters (WAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Voting matters and shareholder proposals
Election of eleven directors to serve for the ensuing year and until successors are elected.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve executive officer compensation on a non-binding basis.
Consideration of any other matters properly brought before the meeting or adjournments.
Board of directors and corporate governance
Eleven nominees listed for election to the board, including individuals with diverse backgrounds and expertise.
Executive compensation and say-on-pay
Shareholders to vote on a non-binding, advisory basis regarding executive officer compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Waters
- Q2 2026 revenue doubled on BDS acquisition, but acquisition costs led to operating losses.WAT
Q2 2026 - Growth is fueled by innovation, premium pricing, and expanding global regulatory drivers.WAT
Leerink’s Global Healthcare Conference 2025 - Double-digit growth, innovation, and integration drive strong performance and future momentum.WAT
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue hit $1.267B with 20% EPS growth, but net loss was $72M from acquisition costs.WAT
Q1 2026 - Strong 2025 results, strategic acquisition, and robust governance drive long-term growth.WAT
Proxy filing - BD integration advances with focus on execution, margin gains, and strong core growth outlook.WAT
TD Cowen 46th Annual Health Care Conference - 2026 guidance projects $6.4B–$6.5B revenue and 9–10% EPS growth after BD acquisition.WAT
Q4 2025 - Q2 beat guidance, with resilient margins and a cautious full-year outlook amid FX and demand headwinds.WAT
Q2 2024 - High single-digit growth and margin expansion targeted, fueled by innovation and high-growth adjacencies.WAT
Investor Day 2025